TY -的T1 -卵巢切除anti-NMDAr脑炎:比较激进和保守的方法(S41.006) JF -神经学乔-神经学六世- 98 - 18补充SP - 633 AU - Yajur Iyengar AU -朱利安赫伯特盟Seth Climans AU -亚历山德首页拉Muccilli盟——格里高利天非盟-理查德Wennberg盟大卫Tang-Wai Y1 - 2022/05/03 UR - //www.ez-admanager.com/content/98/18_Supplement/633.abstract N2 -目的:比较一年期的功能性结果NMDArE患者接受激进与保守的卵巢切除术。背景:切除患者的卵巢畸胎瘤的anti-N-methyl-D-aspartate受体脑炎(NMDArE)与显著地提高神经系统有关。目前缺乏证据的相对安全性和有效性不同的手术治疗方法。设计/方法:NMDArE患者接受卵巢切除术2012年1月1日至2020年12月31日,从两个三级中心回顾性确定。主要结果是好的一年期功能状态,定义为改良Rankin规模(夫人)0 - 2分。激进的方法是定义为一个一步双边卵巢切除术或卵巢切除术术前影像畸胎瘤的证据。Fisher精确检验和Wilcoxon测试被用来比较两组。然后我们进行了固定效应分析将从这个研究结果与其他研究报告功能结果基于如上定义的手术方法。结果:15例中学习。在脑炎发病平均年龄24岁(范围:19 - 73)。平均延迟从出现症状到手术36天(范围:16 - 129)。七个病人(47%)接受积极的手术方法。 Four out of seven (57%) patients in the aggressive approach group had a good outcome, compared with 6/8 (75%) in the conservative approach group (p=0.61). There were no statistically-significant differences in delay from symptom onset to treatment, length of ICU stay, or age between the two groups. One study was included in the meta-analysis (n=29, Dai et al. 2019), which revealed no statistical difference between the two surgical approaches (p=0.18).Conclusions: Aggressive (versus conservative) ovarian resection does not seem to improve neurological outcomes among patients with NMDArE. Clinicians should use caution when considering such surgical approaches.Disclosure: Mr. Iyengar has nothing to disclose. Dr. Hebert has nothing to disclose. Dr. Climans has nothing to disclose. Dr. Muccilli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Muccilli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Muccilli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Parabon Nanolabs. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for DynaMed (EBSCO Health). Dr. Day has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Barrow Law. The institution of Dr. Day has received research support from National Institutes of Health / NIA. The institution of Dr. Day has received research support from Chan Zuckerberg Initiative. The institution of Dr. Day has received research support from Alzheimer's Association. The institution of Dr. Day has received research support from National Institutes of Health / NINDS. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Presenter at regional meeting (CME) with Texas Neurological Society. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Grant Review (honorarium) with Pennsylvania Department of Health . Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Presenter at Annual Meeting (CME) with American Academy of Neurology. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development (CME) with PeerView, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Continuing Education, Inc. Dr. Day has a non-compensated relationship as a Clinical Director with AntiNMDA Receptor Encephalitis Foundation that is relevant to AAN interests or activities. Dr. Wennberg has nothing to disclose. Dr. Tang-Wai has nothing to disclose. ER -